亚洲围产期HIV感染青少年的联合抗逆转录病毒治疗失败:识别、管理与结局
该研究分析了2014-2018年亚洲区域队列中3196例接受至少6个月连续cART的围产期HIV感染青少年,随访中位3.0年,230例(7.2%)发生292次治疗失败事件(161病毒学、128免疫学、11临床),发生率3.78/100人年。治疗失败后6个月内仅31次(10.6%)更换cART,更换者免疫学和病毒学结局优于未更换者;治疗失败后5年死亡和失访累积发生率为18.5%,无失败者为10.1%。结论强调需改进病毒学监测、后续cART可及性及耐药检测。
要点
- 围产期HIV感染青少年cART失败率7.2%,以病毒学失败为主。
- 失败后6个月内仅10.6%更换方案,更换者结局更优。
- 失败后5年死亡/失访累积发生率18.5%,显著高于无失败者10.1%。
核心结论
- 需改进病毒学监测以实现cART失败病毒学判定的益处,并解决后续cART可及性、依从性及耐药检测问题。
研究设计与样本
- 分析2014-2018年亚洲区域队列中接受至少6个月连续cART的围产期HIV感染青少年数据,随访中位3.0年。
主要发现
- 3196例中230例(7.2%)发生292次治疗失败事件(161病毒学、128免疫学、11临床),发生率3.78/100人年。
- 292次失败事件中31次(10.6%)在6个月内更换cART,更换者免疫学和病毒学结局优于未更换者。
- 治疗失败后5年死亡和失访累积发生率为18.5%,无治疗失败者为10.1%。
关键数值与推荐
- 治疗失败依据世界卫生组织(WHO)标准定义。
临床怎么用
- 应加强病毒学监测以识别cART失败,及时评估并更换方案,同时关注依从性和耐药检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination antiretroviral therapy (cART) failure is a major threat to human immunodeficiency virus (HIV) programs, with implications for individual- and population-level outcomes. Adolescents with perinatally acquired HIV infection (PHIVA) should be a focus for treatment failure given their poorer outcomes compared to children and adults. METHODS: Data (2014-2018) from a regional cohort of Asian PHIVA who received at least 6 months of continuous cART were analyzed. Treatment failure was defined according to World Health Organization criteria. Descriptive analyses were used to report treatment failure and subsequent management and evaluate postfailure CD4 count and viral load trends. Kaplan-Meier survival analyses were used to compare the cumulative incidence of death and loss to follow-up (LTFU) by treatment failure status. RESULTS: A total 3196 PHIVA were included in the analysis with a median follow-up period of 3.0 years, of whom 230 (7.2%) had experienced 292 treatment failure events (161 virologic, 128 immunologic, 11 clinical) at a rate of 3.78 per 100 person-years. Of the 292 treatment failure events, 31 (10.6%) had a subsequent cART switch within 6 months, which resulted in better immunologic and virologic outcomes compared to those who did not switch cART. The 5-year cumulative incidence of death and LTFU following treatment failure was 18.5% compared to 10.1% without treatment failure. CONCLUSIONS: Improved implementation of virologic monitoring is required to realize the benefits of virologic determination of cART failure. There is a need to address issues related to accessibility to subsequent cART regimens, poor adherence limiting scope to switch regimens, and the role of antiretroviral resistance testing.
引用
- Bartlett AW, Sudjaritruk T, Mohamed TJ, et al. Identification, Management, and Outcomes of Combination Antiretroviral Treatment Failure in Adolescents With Perinatal Human Immunodeficiency Virus Infection in Asia. Clin Infect Dis. 2021. PMID: 32589711. doi:10.1093/cid/ciaa872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。